'Cancer' Label for Low-Risk Prostate Lesions? Patients Split
But pathologists largely think the name should stay, results of a recent survey show.
Stay updated with breaking news from Ancer Prostate . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
But pathologists largely think the name should stay, results of a recent survey show.
Radiolabeled 89Zr-DFO-girentuximab PET/CT can accurately and noninvasively identify clear cell renal carcinoma, with minimal toxicity, say researchers reporting results from the phase 3 ZIRCON trial.
For patients with metastatic castration-resistant prostate cancer, talazoparib combined with enzalutamide achieved better progression-free survival than enzalutamide alone.
For patients with metastatic castration-resistant prostate cancer with BRCA alterations, rucaparib doubled progression-free survival as compared with docetaxel, abiraterone, or enzalutamide.
"If a patient doesn't achieve remission or very low disease activity, obtaining a radiograph doesn't change what you do … you're going to make a change anyway," Dr. Roy Fleischmann said.